ReviewPharmaceutics2022

Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review.

Yuliya Lytvyn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.